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The Role of Histamine H1 and H4
Receptors in Atopic Dermatitis: From
Basic Research to Clinical Study
Yusuke Ohsawa1 and Noriyasu Hirasawa1
ABSTRACT
Histamine plays important roles in inflammation and nervous irritability in allergic disorders, including atopic
dermatitis (AD). It has been shown to regulate the expression of pruritic factors, such as nerve growth factor
and semaphorin 3A, in skin keratinocytes via histamine H1 receptor (H1R). Furthermore, H1R antagonist re-
duced the level of IL-31, a cytokine involving the skin barrier and pruritus, in chronic dermatitis lesions in NC
Nga mice and patients with AD. Histamine plays roles in the induction of allergic inflammation by activating
eosinophils, mast cells, basophils, and Th2 cells via histamine H4 receptor (H4R). H4R, in addition to H1R, is
expressed on sensory neurons, and a decrease in scratching behaviors was observed in H4R-deficient mice
and mice treated with a H4R antagonist. We found that the combined administration of H1R and H4R antago-
nists inhibited the itch response and chronic allergic inflammation, and had a pharmacological effect similar to
that of prednisolone.
Although the oral administration of H1R antagonists is widely used to treat AD, it is not very effective. In con-
trast, JNJ39758979, a novel H4R antagonist, had marked effects against pruritus in Japanese patients with AD
in a phase II clinical trial. Next generation antihistaminic agents possessing H1R and H4R antagonistic actions
may be a potent therapeutic drug for AD.
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ABBREVIATIONS
AD, atopic dermatitis; BMB, bone marrow-derived basophils; BMMC, bone marrow-derived mast cells; DC,
dendritic cells; DRG, dorsal root ganglia; H1R, histamine H1 receptor; H2R, histamine H2 receptor; H3R, hista-
mine H3 receptor; H4R, histamine H4 receptor; HDC, histidine decarboxylase; IL, interleukine; MDC,
macrophage-derived chemokine; NGF, nerve growth factor; TARC, thymus and activation-regulated
chemokine; TNCB, tri-nitro chlorobenzene; Sema3A, semaphorin 3A; TSLP, thymic stromal lymphopoietin.
INTRODUCTION
Atopic dermatitis (AD) is an allergic inflammatory
disease characterized by intense pruritus, chronic ec-
zematous plaques, and relapsing inflammation in-
duced by repeated exposure to an antigen.1 The
prevalence of AD was reported to be approximately
3% in adults and 25% in children, and has increased by
2- to 3-fold during the last century in industrial coun-
tries.1-3
Inflammation in AD skin involves mast cells,
eosinophils, and Th2 cells, and is associated with his-
tological abnormalities such as scaling, crusting, and
lichenoid papules.4 The cytokine milieu of this in-
flamed skin exhibits Th2-dominant responses indi-
cated by the production of Th2 cytokines including
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interleukin (IL)-4, IL-5, and IL-13, and Th2 chemoki-
nes such as thymus and activation-regulated
chemokine (TARCCCL17) and macrophage-derived
chemokine (MDCCCL22).5-8 Th2 responses are trig-
gered by thymic stromal lymphopoietin (TSLP),
which is produced by keratinocytes9 and epithelial
cells.10 TSLP activates dendritic cells (DC)11 or baso-
phils,12 and these cells induce the differentiation of
Th2 populations as antigen-presenting cells.
Histamine is a well-known mediator of acute in-
ﬂammatory and immediate hypersensitivity re-
sponses. Furthermore, it has recently been shown to
affect chronic inﬂammation and regulate several es-
sential events in immune responses.13 Four types of
histamine receptors have been identified to date. His-
tamine H1 receptor (H1R) mediates the histamine-
induced contraction of airway and vascular smooth
muscle cells, and increases vascular permeability.14
Histamine H2 receptor (H2R) is involved in the re-
lease of gastric acid.15 H1R and H2R are expressed
on many cell types including inflammatory and im-
mune cells and modulate their functions. Histamine
H3 receptor (H3R), which is primarily expressed in
the nervous system, acts as a presynaptic autorecep-
tor in central and peripheral neurotransmission.16
Histamine H4 receptor (H4R), which was cloned in
2000, is mainly expressed on several hematopoietic
cells and plays important roles in the histamine-
induced activation of mast cells, eosinophils, mono-
cytes, DC, and T cells.17-20 In addition to H1R, H4R is
now considered to be a new therapeutic target for
AD, asthma, rhinitis and rheumatoid arthritis.21-24
Vigorous pruritus is the most important issue re-
quiring a therapeutic strategy in AD, more so than al-
lergic inflammation. However, pruritus associated
with AD is poorly controlled clinically. The mediators
of pruritus have been extensively studied,25 and hista-
mine has been shown to be a potent pruritogen when
applied to both normal skin in healthy individuals26
and the lesional skin of AD patients.27 However, al-
though the itching associated with a nettle rash is po-
tently alleviated by H1R antagonists, whether hista-
mine is involved in the pruritus of AD has yet to be
confirmed.
Thus, histamine exerts a range of effects on many
physiological and pathological processes and new
roles are still being elucidated. In this review, we
aimed to briefly summarize current knowledge on
H1R and H4R, and discuss the possibility of therapeu-
tic targets regarding H1R and H4R antagonism both
in vivo and in patients with AD.
H1R
H1R is expressed in many tissues and cells, including
nerves, respiratory epithelia, vascular smooth muscle
cells, endothelial cells, hepatic cells, DC and lympho-
cytes. H1R is coupled to Gq, which activates phos-
pholipase C, and increases intracellular Ca2+ lev-
els.28-32 As a consequence, histamine elicits the con-
traction of respiratory tract or vascular smooth mus-
cles, increases vascular permeability, and induces the
production of prostacyclin and platelet activating fac-
tor by activating H1R.32,33 Thus, almost all immediate
hypersensitivity reactions, which include skin symp-
toms, such as erythema, pruritus, and edema, are
elicited by the activation of H1R.15
The activation of H1R also affects the immune re-
sponses of various immune cells that play a role in al-
lergic dermatitis. Histamine has been shown to en-
hance the production of MCP-1, RANTES, and GM-
CSF in IFN-γ-stimulated keratinocytes.34 It also
upregulates the antigen-presenting capacity of DC,
and leads to Th1 polarization through H1R.35 H1R ex-
pression levels were previously shown to be higher in
Th1 cells than in Th2, Th17, or Treg cells,36-39
whereas H2R is preferentially expressed on Th2
cells.40 Cytokines such as IL-3 enhance H1R expres-
sion in Th1 cells, but not in Th2 cells.36 Histamine
was shown to directly augment Th1 responses by
triggering H1R, while both Th1- and Th2-type re-
sponses were suppressed by H2R.31 In addition, hista-
mine, via H1R, has a chemotactic effect on T cells,41
and decreases the suppressive functions of Treg cells
by reducing the expression of CD25 and Foxp3.39
Nerve growth factor (NGF) level in the skin horny
layers of patients with AD is useful as a biomarker for
disease severity, especially pruritus.42 H1R is also ex-
pressed in keratinocytes43 and dermal dendritic
cells44 in the skin tissue, and histamine increases the
production of NGF via H1R in human keratinocytes.45
The secretion of NGF is caused by the phosphoryla-
tions of PKC, ERK and the activation of AP-1 from
H1R. Furthermore, we confirmed that histamine
regulated the expression of semaphorin 3A (Sema3A)
via H1R, in mouse keratinocytes (Fig. 1A, B).
Sema3A has been identified as a guidance molecule
of nerve fibers and regulates the motility of dorsal
root ganglia (DRG) growth cones and axonal mor-
phogenesis.46,47 Sema3A expression levels in the epi-
dermis were shown to be markedly lower in patients
with AD than in healthy volunteers.48 In human
keratinocytes, the expression of Sema3A is changed
by cellular Ca2+ concentration, so the activation of
H1R, coupled to Gq, might be down-regulated them
by Ca2+ mobilization.49 Thus, histamine may be in-
volved in the itch response in local skin lesions by in-
creasing NGF production and decreasing Sema3A ex-
pression levels via H1R, in addition to the direct
stimulation of sensory neurons.50
Histamine was recently shown to induce the pro-
duction of IL-31, which plays a role in pruritus and
skin barrier function in AD.51,52 A previous study was
reported that IL-31 was predominantly produced by
Th2-skewed activated T cells in vitro.53 Transgenic
mice overexpressing IL-31 exhibit spontaneous pruri-
tus and develop severe dermatitis.54 In human dis-
Histamine in Atopic Dermatitis
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Fig.　1　The new roles of H1R and H4R-mediated pathways, keratinocytes, mast cells, and basophils in vitro. H1R and H4R 
mRNA levels were determined in the mouse keratinocyte cell line PAM212 (A). PAM212 cells were incubated for 30 min in me-
dium containing olopatadine and then stimulated with histamine at 10 μM for 3 h, and the expression levels of Sema3A mRNA 
were then determined (B). Mouse bone marrow-derived mast cells (BMMC) were treated with olopatadine or JNJ7777120 for 
30 min, and then stimulated with DNP-BSA for 24 hrs. Histamine (C) and TARC (D) levels were measured in the supernatant. 
Signifi cance; **P < 0.01 and ***P < 0.001 vs. DNP-BSA stimulation. The mRNA levels of histamine receptors were analyzed in 
bone marrow-derived basophils (BMB) by real-time PCR (E). Histamine was added to the bottom chamber in the chemotaxis 
assay for BMB. BMB treated with JNJ7777120 or olopatadine for 30 min were added to the top chamber. After incubation for 
24 hrs, transwells were removed and the number of cells that infi ltrated into the bottom chamber was counted (F). Signifi cance; 
**P < 0.01 vs. histamine alone.
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eases, IL-31 was significantly overexpressed in pru-
ritic atopic dermatitis and, at its highest levels, in pru-
rigo nodularis, one of the most pruritic forms of
chronic skin inflammation.52 Olopatadine, an H1R an-
tagonist, improved IL-31 levels in the lesioned skin of
Dermatophagoides farinae applied dermatitis in NC
Nga mice.55 Otsuka et al. also reported that the ad-
ministration of cetirizine, an H1R antagonist, de-
creases IL-31 levels in the serum of AD patients.56
Thus, histamine has the ability to induce several
skin symptoms in AD, including pruritus, and affects
immune responses. Nevertheless, evidence to show
that the oral administration of H1R antagonists allevi-
ates AD is lacking.57
H4R
H4R is expressed not only on immune cells, but also
on other cell types including intestinal epithelia,
spleen, lung, synovial tissue, central nervous system,
sensory neurons, and also cancer cells.58-64 H4R is
coupled to Gαio proteins, therefore, the stimulation
of H4R reduces forskolin-induced cAMP forma-
tion.65,66 This stimulation also leads to the activation
of mitogen-activated protein kinase and enhanced
Ca2+ mobilization.67
H4R mediates the pro-inflammatory responses of
histamine in both autocrine and paracrine manners.
Histamine via H4R increases the expression of adhe-
sion molecules as well as cell shape changes and re-
arrangement of the actin cytoskeleton, leading to the
increased movement of eosinophils.18 Mast cells are a
major source of, and also respond to histamine. Mast
cells are attracted to allergic lesions by the histamine
produced by dendritic cells during the effector
stage.68 The activation of H4R on mast cells results in
Ca2+ mobilization and chemotaxis, without affecting
degranulation, which enables the selective recruit-
ment of effector cells and amplification of histamine-
induced allergic responses.17 We recently elucidated
a novel action of histamine that was mediated by H4R
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using bone marrow-derived mast cells (BMMC).69
H4R antagonists markedly inhibited the production of
TARC by antigen-stimulated BMMC (Fig. 1C, D).
Since histamine was released from BMMC stimu-
lated with the antigen, the histamine released may
have induced the production of these chemokines.
TARC is a chemokine that acts through CCR4 ex-
pressed by Th2 cells, and is known to be an impor-
tant mediator in human Th2-type immunity.70,71
Similar to mast cells, basophils also express the
high affinity IgE receptor FcεRI on their surface and
release chemical mediators such as histamine follow-
ing antigen stimulation.72 However, basophils and
mast cells differ in several important aspects, such as
anatomical localization, the production of cytokines,
and antigen-presenting activity.73-75 Basophils have
the ability to induce Th2-skewing with haptens and
peptide antigens, but not protein antigens upon epicu-
taneous immunization.11,76 Shiraishi et al. demon-
strated the histamine-induced chemotaxis of bone
marrow-derived basophils (BMB), but not H4R-
deficient BMB.77 We also confirmed that BMB pref-
erentially expressed H4R mRNA over those of the
other histamine receptors (Fig. 1E), and the
histamine-induced chemotaxis of BMB was blocked
by an H4R antagonist, but not by an H1R antagonist
(Fig. 1F). A recent study reported that the antigen-
IgE mediated activation of basophils occurred in the
peripheral blood of patients with AD.78 Since baso-
phils not only initiate allergic inflammation, but also
play a role in maintaining the allergy march,79 H4R
may play important roles in the regulation of baso-
phils in AD.
Among the Th subsets, the mRNA and protein of
H4R are preferentially expressed in Th2 cells over
Th1 cells and naive T cells.80 The expression of IL-31
mRNA by stimulating H4R is upregulated though the
activation of AP-1 in Th2 cells and peripheral blood
mononuclear cells from patients with AD.80 Addition-
ally, Th17 cells polarized by IL-1β together with IL-23
also expressed H4R on the mRNA and protein levels.
Since Th17 cells preferentially infiltrate the acute skin
lesions of patients with AD,81 H4R may contribute to
the pathogenesis of allergic inflammation by activat-
ing not only Th2 cells, but also Th17 cells.
Using H4R-deficient mice or H4R antagonist, H4R
was shown to play roles not only in allergic inflamma-
tion, but also in pruritus.82-87 The anti-allergic effects
of H4R antagonists were mainly evaluated in a derma-
titis mouse model (Table 1). Dunford et al. clarified
the involvement of H4R in the itch responses induced
by allergic mechanisms.82 A decrease in scratching
behaviors was observed in H4R-deficient mice or
mice treated with the H4R antagonist, JNJ7777120.
Regarding the mechanisms of histamine-mediated
pruritus, Thurmond et al. suggested that both H1R
and H4R are expressed on C-afferent fiber terminals,
and also that these antagonists may directly inhibit
the transmission of itching responses from the pe-
ripheral to central nervous system.87 Rossbach et al.
detected the expression of H1R, H3R, and H4R on
skin innervating sensory neurons isolated from the
DRG.88 Using single-cell calcium imaging, they re-
vealed that histamine induced an increase in calcium
levels in a subset of skin-specific sensory neurons by
activating H1R and H4R as well as inhibiting H3R.
Furthermore, changes in fluorescence intensity ac-
companying the Ca2+ influx were stronger with the
H4R agonist than with the H1R agonist and H3R in-
verse agonist. Therefore, H4R is considered to have
essential roles in itch responses via C-fibers orand
DRG.
EFFECTS OF THE CO-ADMINISTRATION OF
H1R ANTAGONISTS AND H4R ANTAGO-
NISTS IN ALLERGIC DERMATITIS MODELS
Previously, it has been reported skin inflammation in-
duced each antigen improved by antagonisms of H1R
or H4R in vivo. H1R antagonists, used in clinical prac-
tice such as olopatadine,55,69,89 pyrilamine,90 cetiriz-
ine83 and fexofenadine,91 were confirmed the useful-
ness to allergic dermatitis models in mice. However,
an antagonism of H1R has only limited effects in skin
inflammation. Rossbach et al. reported that the com-
bination of H4R and H1R antagonism had prophylac-
tic effects on acute hapten-induced scratching, but
not dermatitis.83 We recently confirmed that co-
administration of H1R and H4R antagonists exhibited
therapeutic efficacy in chronic dermatitis.69 When
TNCB was repeatedly applied to NCNga mice with
chronic dermatitis, H4R antagonist suppressed
TNCB-induced scratching behavior, and the combi-
nation with an H1R antagonist had an additive effect.
Such synergistic effects have also been reported in an
acute inflammatory model by Rossbach et al.83 and
chemical-induced pruritus model by Dunford et al..82
We confirmed that the repeated administration of
H1R and H4R antagonists inhibited both the itch re-
sponse and chronic allergic inflammation, while the
single administration of H4R and H1R antagonists
also markedly inhibit scratching behaviors.69 This
combined administration potentiated anti-inflamm-
atory effects, and had a pharmacological effect similar
to that of prednisolone. More recently, Mahapatra et
al. reported Th2-dependent antigen-specific skin in-
flammation using OVA-allergen attenuates by combi-
nation therapies with H1R and H4R antagonists, as
well as hapten-induced model.92 These findings sug-
gest that the antagonism of H4R is not only useful for
pruritus and allergic inflammation in vivo, but also
has superior effects if the antagonism of H1R is
added. The combined treatment with H4R antagonist
plus H1R antagonist potentiated the therapeutic ef-
fects similar to those of prednisolone in chronic der-
matitis.
Histamine in Atopic Dermatitis
Allergology International Vol 63, No4, 2014 www.jsaweb.jp 537
Table　1　Effects of H1R and/or H4R antagonists on dermatological disorders in vivo
Evaluation Induction Mouse Compounds Schedule Results ReferenceNo.
Pruritus
Antigen-IgE, 
Histamine, 
Compound 
48/80
CD-1
JNJ7777120, 
diphenhydr-
amine
prophylactic
Signifi cant inhibition was observed when 
JNJ7777120 was administered in conjunc-
tion with diphenhydramine, and this was 
more effective to that by JNJ7777120 
alone.
82
Pruritus
(& Dermatitis) TDI BALB/c
JNJ7777120, 
cetirizine prophylactic
The combination of JNJ7777120 and ceti-
rizine resulted in the strongest inhibition of 
scratching behavior but not allergic derma-
titis.
83
Acute
dermatitis TNCB, TPA BALB/c
Pyrilamine, 
thioperamide prophylactic
In TNCB-induced biphasic ear swelling, 
pyrilamine and thioperamide inhibited early 
phase and late phase reaction, respective-
ly.
21
Acute
dermatitis
OVA + OVA 
primed Th2 
cells
BALB/c JNJ7777120, mepyramine prophylactic
Mepyramine or JNJ7777120 reduced the 
infi ltration of Th2 cells to the skin lesion. 
The levels of cytokines in skin lymph node-
derived cells were reduced by the com-
bined application.
92
Sub-acute
dermatitis TNCB c57BL/6
JNJ7777120, 
olopatadine prophylactic
Combined therapy with JNJ7777120 and 
olopatadine decreased serum IgE and Th2 
cytokines more than monotherapy with 
olopatadine.
86
Sub-acute 
dermatitis Derf NC/Nga Olopatadine therapeutic
Olopatadine signifi cantly suppressed sc-
ratch ing, and improved the dermatitis 
score
54
Chronic
dermatitis Spontaneous Ds-Nh Olopatadine prophylactic
Olopatadine suppressed TSLP and Th2 
cytokines levels in lesional skin. 89
Chronic
dermatitis
Diet with low 
Mg2+ and Zn2+ HR-1 Fexofenadine prophylactic
Fexofenadine signifi cantly decreased a 
scratching frequency and the level of eo-
taxin in plasma.
91
Pruritus & 
Chronic
dermatitis
TNCB NC/Nga JNJ7777120, olopatadine therapeutic
JNJ7777120 attenuated scratching behav-
ior and improved dermatitis and augment-
ed by the combined treatment with olopa-
tadine.
69
Pruritus & 
Chronic
dermatitis
TNCB HR-1 JNJ7777120, fexofenadine therapeutic
JNJ7777120 reduced scratching behavior 
and ameliorated skin lesions, whereas 
fexofenadine had no such effect and did 
not reduce infl ammation.
85
TDI, Toluene-2,4-diisocyanate; TNCB, 2,4,6-trinitro-1-chlorobenzene; TPA, 12-O-tetradecanoylphorbol 13-acetate; FITC, fl uorescein iso-
thiocyanate; Derf, Dermatophagoides farinae.
CLINICAL EFFECTS OF H1R ANTAGONISTS
ON AD
To treat for AD, topical glucocorticoids, calcineurin
inhibitor ointments, cyclosporine, and anti-histamine
and anti-allergic agents are prescribed medical treat-
ments in Japan.93 Histamine levels were shown to be
higher in the plasma and skin lesions of AD patients
than in healthy donors.94,95 However, evidence for the
efficacy of H1R antagonists as an oral drug is lacking
and is generally not supported by randomized con-
trolled trials. There is an only report that fexofena-
dine 60 mg twice daily for 7 days was significantly de-
creased the severity of pruritus compared with pla-
cebo.96 On the other hand, the topical treatment of
AD with H1R antagonists was also examined in clini-
cal studies. Although their efficacies remain contro-
versial,97,98 some H1R antagonists, such as doxe-
pin,99,100 diphenhydramine,101 and loratadine,102 had
beneficial effects on pruritus in AD. In human kerati-
nocytes, histamine decreases the formulation of tight
junctions and the expression of filaggrin, a gene re-
sponsible for AD, via H1R (Table 2).43 As described
above, histamine also regulates neuron guidance fac-
tors such as NGF and Sema3A via H1R, in epidermis.
These findings indicate that H1R is partly involved in
the pathogenesis of AD-lesional skin.
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Table　2　Expression and functional characteristics of histamine, H1R, and H4R in healthy donors and atopic dermatitis patients
Donor Sample Expression Functions ReferenceNo.
Healthy Keratinocytes H1R Histamine suppresses epidermal keratinocyte differentiation and impaired skin barrier function via H1R. 43
Healthy Keratinocytes H1R
Promotion of RANTES and GM-CSF secretion and augmen-
tation of the IFN-γ-induced release of the chemokines MCP1, 
RANTES, MIP3α, IP-10, and GM-CSF.
34
Healthy Th17 cells H4R Increased production of IL-17 and induction of AP-1 in Th17 cells by stimulation with histamine of an H4R agonist. 38
Healthy Th2 cells H4R H4R is highly expressed on Th2 cells by IL-4 and activation with H4R upregulates IL-31 mRNA in Th2 cells. 80
Healthy Langerhans cells H4R
Increased migration from the epidermis and downregulation 
of the production of CCL2 via H4R activation. 103
Atopic dermatitis Plasma Histamine Higher in patients with AD than in healthy volunteers. 94, 95
Atopic dermatitis Lymphocytes H4R STAT1 phosphorylation and cleavage are regulated by H4R in human atopic and non-atopic lymphocytes. 62
Atopic dermatitis Dendritic cells H4R
Histamine or an H4R agonist downregulates the production 
of CCL2 and upregulates IFN-γ. H4R may contribute to the 
shift from a Th2 to Th1 milieu, as seen in the transition from 
acute to chronic lesions of AD.
104
Atopic dermatitis Keratinocytes H1R and H4R Highly expression in keratinocytes of patients with AD, and induction of proliferation via activation with H4R. 105
CLINICAL TRIALS OF H4R ANTAGONISTS
ON AD
H4R, in addition to H1R, is expressed on cells consti-
tuting the epidermis and not only on immune cells,
obtained from healthy volunteers103 and AD pa-
tients,104 and have functional roles in these cells (Ta-
ble 2). H4R is more abundantly expressed in kerati-
nocytes from patients with AD than in those from
healthy donors.105 The H4R agonist, 4-methylhis-
tamine, was shown to induce the proliferation of
keratinocytes from patients with AD.105 Thus, H4R is
also involved in the pathogenesis of AD. Before now,
anti-histamine drugs with H4R antagonism are un-
known in clinic.106 Only alcaftadine, which is an anti-
histamine drug for treatment of allergic conjunctivi-
tis, has an affinity with H4R (Ki = 2.9 μM), but it has
high selectivity with H1R (Ki = 3.1 nM).107 It is con-
sidered alcaftadine has a no-effective toward H4R in
clinic since it has high sensitivity of nearly 1,000-fold,
compared with H1R to H4R.
The safety and efficacy of JNJ39758979, a selective
and high affinity H4R antagonist, were recently as-
sessed at 100 or 300 mgday for 6 weeks in patients
with AD.108-110 The primary endpoint (Eczema Area
and Severity Index score at week 6) was not signifi-
cant, although both active groups showed numerical
improvements over the placebo group. Significant
symptomatic improvements were observed in patient-
reported itch severity and duration. In addition, the
effects of JNJ39758979 on histamine-induced itch in
healthy donors were evaluated in phase I study. Com-
pared with placebo or cetirizine, which is an H1R an-
tagonist, the reduction of pruritus score was signifi-
cant for JNJ39758979.111 Interestingly enough, JNJ
39758979 was ineffective against wheal and flare reac-
tions associated with intradermal histamine injection,
while these effects were almost completely elimi-
nated by cetirizine. These results suggested hista-
mine induces flare response and pruritus by activa-
tion with H1R and H4R, respectively, in skin tissues
of human. JNJ39758979 showed significantly anti-
pruritic effects in human, but agranulocytosis oc-
curred in two patients administered 300 mg in phase
II trial. This was attributed to the off-target effects of
JNJ39758979 and the sponsor terminated this clinical
study. The finding obtained from clinical trials is that
JNJ39758979 had an anti-pruritic effect in moderate
AD patients, and healthy subjects with histamine
challenge.
CONCLUSIONS
We summarized the usefulness of H1R and H4R an-
tagonists to treat chronic allergic dermatitis in mice
and AD patients in this review. Histamine exhibits
various actions on skin disorders through H1R and
H4R. Histamine regulates nerve fiber interventions
by decreasing the expression of Sema3A mRNA and
increasing NGF levels via H1R in keratinocytes, and
directly activates sensory neurons via H1R and H4R.
The increase in NGF levels and decrease in the ex-
pression of Sema3A was also been confirmed in the
Histamine in Atopic Dermatitis
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Fig.　2　H1R and H4R pathways in chronic allergic dermatitis.
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skin lesions of AD patients, as well as in vivo. Fur-
thermore, histamine, via H4R, activates the effector
cells of allergic responses, such as mast cells, baso-
phils, and eosinophils, and induces the production of
TARC, which reflects the clinical severity of AD. His-
tamine also regulates the functions of not just Th2
cells but Th1 and Th17 cells, via various receptors.
Thus, histamine affects various cells located in skin
tissues via mainly H1R and H4R (Fig. 2). Especially, it
is an interesting knowledge that IL-31, a cytokine
which induces of pruritus and Th2-type allergic re-
sponse as a new biomarker, is regulated via hista-
mine H1R and H4R.
Topical glucocorticoids frequently cause skin atro-
phy and elicit side effects due to their systemic ad-
ministration. We found that the co-administration of
an H1R antagonist and H4R antagonist had potent in-
hibitory effects that were equal to those of steroids in
a chronic allergic dermatitis mouse model, and JNJ
39758979 exhibited anti-pruritic effects in moderate
AD patients. More recently, ZPL-3893787 for Ziarco
pharm, which has entered into an agreement from
Pfizer Inc., started phase I study for allergic diseases.
Next generation antihistaminic agents with H1R and
H4R antagonistic actions should be developed in the
future to treat patients with AD.
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